InsiderTrades

Form 4 for LENZ LENZ Therapeutics, Inc.

Accepted 2021-07-01 00:00:00 ET · period of report 2021-01-13 · accession 0000899243-21-027015 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-07-01 2021-06-29 LENZ Stultz Katherine V COO C - Cnv Deriv — +8,126 216.0K +4% —
D 2021-07-01 2021-06-29 LENZ Stultz Katherine V COO C - Cnv Deriv $0.00 -19.8K 0 -100% $0
DM 2021-07-01 2021-01-13+ LENZ Stultz Katherine V COO A - Grant $0.2385 +419.3K 89.9K New +$100.0K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-06-29 C A 8,126 — 216,020 D — — (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
2 Derivative Series B Preferred Stock 2021-06-29 C D 19,763 $0.00 0 D — · — to — 8,126 Common Stock (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
3 Derivative Stock Option (right to buy) 2021-01-13 A A 99,753 $0.00 99,753 D $0.3 · — to 2031-01-12 99,753 Common Stock (F2) On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. (F4) 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after August 31, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.
4 Derivative Series B Preferred Stock 2021-03-11 A A 19,763 $5.06 19,763 D — · — to — 8,126 Common Stock (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
5 Derivative Stock Option (right to buy) 2021-03-17 A A 209,846 $0.00 209,846 D $6.11 · — to 2031-03-16 209,846 Common Stock (F2) On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. (F5) 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.
6 Derivative Stock Option (right to buy) 2021-03-17 A A 89,934 $0.00 89,934 D $6.11 · — to 2031-03-16 89,934 Common Stock (F2) On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. (F6) The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.